ChromaDex (NASDAQ:CDXC) Issues Quarterly Earnings Results

ChromaDex (NASDAQ:CDXC) posted its quarterly earnings results on Thursday. The company reported $0.02 earnings per share (EPS) for the quarter, Zacks reports. The business had revenue of $25.58 million for the quarter, compared to analyst estimates of $23.70 million. ChromaDex had a return on equity of 5.06% and a net margin of 1.62%. During the same period last year, the company earned ($0.01) EPS. ChromaDex updated its FY 2024 guidance to EPS.

ChromaDex Stock Up 67.9 %

Shares of NASDAQ CDXC traded up $2.37 on Friday, reaching $5.86. 37,543,352 shares of the company’s stock traded hands, compared to its average volume of 264,220. The business’s 50 day simple moving average is $3.53 and its two-hundred day simple moving average is $3.23. ChromaDex has a 12 month low of $1.32 and a 12 month high of $5.98. The company has a market cap of $444.95 million, a price-to-earnings ratio of 586.59 and a beta of 1.88.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of ChromaDex in a research report on Friday, August 9th.

Insider Transactions at ChromaDex

In other ChromaDex news, Director Kristin Patrick sold 23,000 shares of ChromaDex stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $3.57, for a total value of $82,110.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 9.64% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.